USP22 and carcinoma: The expression of USP22 dramatically affects the expression of MRP1, which mediates MDR in numerous carcinomas by pumping anticancer agents out of cells.[16] Downregulation of USP22 could inhibit the AKT/GSK‐3β pathway and further suppress the expression of MRP1 (Figure 4a[8b] As illustrated in Figure 4b, MRP1, p‐AKT (Ser473) and phosphorylated GSK‐3β (p‐GSK‐3β) were downregulated in Huh‐7 cells treated with Gal‐LPs and Gal‐SLPs.